Results 171 to 180 of about 8,896 (223)

Intensive care scores predict outcomes in patients receiving cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. [PDF]

Front Surg
Wimmer J, Acs M, Bohus G, Hauer P, Müller V, Bogovic N, Kupke P, Slowik P, Schlitt HJ, Hornung M, Werner JM.   +10 more
europepmc   +1 more source

Correction to "Implementation of a Multidisciplinary Enhanced Recovery After Surgery (ERAS) Program for Cytoreductive Surgery (CRS) With Hyperthermic Intraperitoneal Chemotherapy (HIPEC)". [PDF]

J Surg Oncol
europepmc   +1 more source

Hyperthermic intraperitoneal chemotherapy in ovarian cancer: an update [PDF]

Hormone Molecular Biology and Clinical Investigation, 2020
Abstract In the treatment of advanced-stage epithelial ovarian cancer (EOC)-associated surgery and chemotherapy with intravenous platinum/taxane-based therapy most patients had early or late recurrence. Prevention of progression and recurrence is a major objective for the management of EOC.
Revaux, A., Carbonnel, M., Kanso, F., Naoura, I., Asmar, J., Kadhel, P., Ayoubi, J.-M.   +6 more
openaire   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer

Gynecologic Oncology, 2004
To evaluate the clinical effect of intraperitoneal hyperthermic chemotherapy (IPHC) in ovarian cancer patients.We retrospectively reviewed 117 stages Ic-III ovarian cancer patients, who were diagnosed at the Gynecology Department of Kangnam St. Mary's Hospital between January 1994 and January 2000. Of these, 57 patients underwent cytoreductive surgery (
Hyun Sun Ko, Yong Gyu Park, Seung Jo Kim
exaly   +3 more sources

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

Annals of Surgical Oncology, 2023
Hyperthermic intraperitoneal chemotherapy (HIPEC) is a treatment modality that aims to target the main site of tumor dissemination in ovarian cancer, the peritoneum, by combining the benefits of intraperitoneal chemotherapy with the synergistic effects of hyperthermia all during a single administration at the time of cytoreductive surgery. High-quality
Julia H, Gelissen, Naomi N, Adjei, Blair, McNamara, Levent, Mutlu, Justin A, Harold, Mitchell, Clark, Gary, Altwerger, Peter R, Dottino, Gloria S, Huang, Alessandro D, Santin, Masoud, Azodi, Elena, Ratner, Peter E, Schwartz, Vaagn, Andikyan   +13 more
openaire   +2 more sources

Peritoneal Cancers and Hyperthermic Intraperitoneal Chemotherapy

Surgical Clinics of North America, 2020
Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy is an aggressive, potentially curative approach used to treat locoregional disease associated with primary and secondary malignancies of the peritoneum. It involves resection of all macroscopic disease larger than 2.5 mm, followed by instillation of hyperthermic chemotherapy ...
Eric, Pletcher, Elizabeth, Gleeson, Daniel, Labow   +2 more
openaire   +2 more sources

Hyperthermic Intraperitoneal Chemotherapy

Advances in Anesthesia, 2005
Cancer treatment frequently requires a multimodality approach, involving surgical resection(s), radiotherapy, and chemotherapy. Advanced surgical approaches allow for the combination of two of these, offering patients intraoperative radiotherapy with surgical resection or intraoperative chemotherapy targeted and limited to a particular body region. The
Alicia M. Kowalski, Thomas B. Dougherty
openaire   +1 more source

Hyperthermic intraperitoneal chemotherapy for treating ovarian cancer

JAAPA, 2021
ABSTRACT Hyperthermic intraperitoneal chemotherapy (HIPEC) has been used for decades as a treatment for disseminated abdominal malignancies, including pseudomyxoma peritonei and peritoneal mesothelioma. HIPEC had been used to treat recurrent ovarian cancer only when curative options were lacking, but new data indicate that it may be suitable ...
Shilpa, Gajarawala, Jessica, Pelkowski, Rose, Dorian, Amanda, Stanton, Tri, Dinh   +4 more
openaire   +2 more sources